2018
Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma
Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Journal Of Hepatology 2018, 70: 700-709. PMID: 30553841, PMCID: PMC10878126, DOI: 10.1016/j.jhep.2018.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Duct NeoplasmsCancer-Associated FibroblastsCell Line, TumorCholangiocarcinomaDisease Models, AnimalEndothelial CellsHeterograftsHumansImatinib MesylateLiverLymphangiogenesisLymphokinesMaleMiceMice, SCIDMyofibroblastsPlatelet-Derived Growth FactorProtein Kinase InhibitorsRatsRats, Inbred F344Receptor, Platelet-Derived Growth Factor betaVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CConceptsCancer-associated fibroblastsLymphatic endothelial cellsCholangiocarcinoma specimensMetastatic spreadStromal reactionLiver myofibroblastsGrowth factorExtensive stromal reactionLymph node metastasisEarly metastatic spreadLevels of VEGFBH3 mimetic navitoclaxPlatelet-derived growth factorRole of PDGFVascular growth factorsTumor-associated lymphangiogenesisVEGF-C secretionTransendothelial electric resistanceCholangiocarcinoma invasivenessHuman lymphatic endothelial cellsCurative therapyNode metastasisBiliary treeEarly metastasisPDGFRβ inhibitorMyofibroblast proliferation and heterogeneity are supported by macrophages during skin repair
Shook BA, Wasko RR, Rivera-Gonzalez GC, Salazar-Gatzimas E, López-Giráldez F, Dash BC, Muñoz-Rojas AR, Aultman KD, Zwick RK, Lei V, Arbiser JL, Miller-Jensen K, Clark DA, Hsia HC, Horsley V. Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair. Science 2018, 362 PMID: 30467144, PMCID: PMC6684198, DOI: 10.1126/science.aar2971.Peer-Reviewed Original ResearchConceptsDifferential gene expressionAdipocyte precursorsExtracellular matrix moleculesGene expressionTransplantation assaysMatrix moleculesFactor C.Factor 1Insulin-like growth factor-1Cell populationsTissue resilienceDistinct subpopulationsGrowth factor-1Profibrotic cellsTissue repairMultiple mouse modelsECM depositionSkin repairTissue dysfunctionProliferationMouse modelMyofibroblastsWoundingMacrophagesRepairCell Autonomous and Non-cell Autonomous Regulation of SMC Progenitors in Pulmonary Hypertension
Sheikh AQ, Saddouk FZ, Ntokou A, Mazurek R, Greif DM. Cell Autonomous and Non-cell Autonomous Regulation of SMC Progenitors in Pulmonary Hypertension. Cell Reports 2018, 23: 1152-1165. PMID: 29694892, PMCID: PMC5959296, DOI: 10.1016/j.celrep.2018.03.043.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionMyeloid cellsPlatelet-derived growth factor receptor βGrowth factor receptor βKruppel-like factor 4Muscle cell markersAttractive therapeutic targetHypoxia-inducible factor-1Vascular muscularizationDistal migrationNormal lungSmall arteriolesMuscle expansionHypertensionTherapeutic targetNon-cell autonomous pathwaysReceptor βCell expressionCell inductionCell markersSMC progenitorsEndothelial cellsFactor 1Factor 4Muscularization
2013
Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma
Cadamuro M, Nardo G, Indraccolo S, Dall'Olmo L, Sambado L, Moserle L, Franceschet I, Colledan M, Massani M, Stecca T, Bassi N, Morton S, Spirli C, Fiorotto R, Fabris L, Strazzabosco M. Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma. Hepatology 2013, 58: 1042-1053. PMID: 23505219, PMCID: PMC3732815, DOI: 10.1002/hep.26384.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBenzamidesBile Duct NeoplasmsBile Ducts, IntrahepaticCell Line, TumorCell MovementCell ProliferationCells, CulturedCholangiocarcinomaEpithelial-Mesenchymal TransitionFibroblastsHeterograftsHumansImatinib MesylateIn Vitro TechniquesLymphokinesMaleMiceMice, SCIDPiperazinesPlatelet-Derived Growth FactorPyrimidinesrho GTP-Binding ProteinsSignal TransductionConceptsCancer-associated fibroblastsPlatelet-derived growth factorEpithelial-mesenchymal transitionCCA cellsSecretion of PDGFRole of PDGFGrowth factorAbundant stromal reactionAlpha-smooth muscle actinPDGF-D expressionNovel therapeutic approachesPotential therapeutic targetSmooth muscle actinCCA cell linesPDGF-D signalingFibroblast migrationC-Jun N-terminal kinaseEMT biomarkersImmunodeficient miceStromal reactionTherapeutic approachesStroma interactionsTherapeutic targetCholangiocarcinomaMesenchymal markers
2010
Recombinant Fv-Hsp70 Protein Mediates Neuroprotection After Focal Cerebral Ischemia in Rats
Zhan X, Ander BP, Liao IH, Hansen JE, Kim C, Clements D, Weisbart RH, Nishimura RN, Sharp FR. Recombinant Fv-Hsp70 Protein Mediates Neuroprotection After Focal Cerebral Ischemia in Rats. Stroke 2010, 41: 538-543. PMID: 20075343, PMCID: PMC2957177, DOI: 10.1161/strokeaha.109.572537.Peer-Reviewed Original ResearchConceptsFocal cerebral ischemiaCerebral ischemiaInfarction volumeSensorimotor functionSaline-treated control groupIntraluminal suture techniqueExperimental ischemic strokeExperimental stroke modelsMiddle cerebral arteryOnset of ischemiaInfarct volumeIschemic brainIschemic strokeCerebral arteryFocal ischemiaControl brainsStroke modelTail veinIschemiaControl groupSuture techniqueWestern blotEndogenous Hsp70RatsBrain
2007
An Inflammatory Pathway of IFN-γ Production in Coronary Atherosclerosis
Ranjbaran H, Sokol SI, Gallo A, Eid RE, Iakimov AO, D’Alessio A, Kapoor JR, Akhtar S, Howes CJ, Aslan M, Pfau S, Pober JS, Tellides G. An Inflammatory Pathway of IFN-γ Production in Coronary Atherosclerosis. The Journal Of Immunology 2007, 178: 592-604. PMID: 17182600, DOI: 10.4049/jimmunol.178.1.592.Peer-Reviewed Original ResearchConceptsIL-12/ILIFN-gamma-inducible chemokinesCoronary atherosclerosisIL-12IL-18IFN-gammaPlasma levelsT cellsTh1-type cytokine productionHuman atherosclerotic coronary arteriesAcute coronary syndromeSubset of patientsHuman coronary atherosclerosisTh1-type cytokinesC-reactive proteinIFN-γ productionElevated plasma levelsPlasma of patientsInnate immune responseAtherosclerotic coronary arteriesCoronary syndromeSystemic inflammationCardiac catheterizationCardiopulmonary bypassGamma secretion
2006
Use of Beryllium Lymphocyte Proliferation Testing for Screening of Asymptomatic Individuals: An Evidence-Based Assessment
Borak J, Woolf SH, Fields CA. Use of Beryllium Lymphocyte Proliferation Testing for Screening of Asymptomatic Individuals: An Evidence-Based Assessment. Journal Of Occupational And Environmental Medicine 2006, 48: 937-947. PMID: 16966961, DOI: 10.1097/01.jom.0000232548.03207.9f.Peer-Reviewed Original ResearchConceptsAsymptomatic individualsLymphocyte proliferation testingProliferation testingBurden of sufferingChronic beryllium diseaseComputerized literature searchInsufficient scientific evidenceClinical benefitPreventive servicesEvidence-based assessmentRoutine screeningBeryllium diseaseBeryllium sensitizationEarly interventionHand searchLiterature searchBeLPTEarly detectionScientific evidenceMarked intraRelevant bibliographiesInterlaboratory variabilityIndividualsScreeningEvidence
2005
Antibody Mediated Transduction of Therapeutic Proteins into Living Cells
Hansen JE, Weisbart RH, Nishimura RN. Antibody Mediated Transduction of Therapeutic Proteins into Living Cells. The Scientific World JOURNAL 2005, 5: 782-788. PMID: 16170440, PMCID: PMC5936519, DOI: 10.1100/tsw.2005.98.Commentaries, Editorials and LettersMeSH KeywordsAnimalsAutoantibodiesBiological Transport, ActiveCells, CulturedDrug Delivery SystemsEndocytosisGene Products, tatHIV-1HumansImmunoglobulin FragmentsLymphokinesMicePeptide FragmentsProtein TransportProteinsSialoglycoproteinsSignal Transductiontat Gene Products, Human Immunodeficiency VirusConceptsProtein transduction domainTransduction domainNovel protein transduction domainTherapeutic proteinsReceptor-mediated endocytosisSuch proteinsHIV-1 Tat proteinCell-penetrating peptidesMAb 3E10Active proteinLiving cellsCell membraneProteinTat proteinProtein therapyCellsSingle-chain fragmentTherapeutic peptidesRecent studiesFv fragmentDomainFragmentsDirect deliveryEndocytosisTransductionAn intracellular delivery vehicle for protein transduction of micro-dystrophin
Weisbart RH, Hansen JE, Nishimura RN, Chan G, Wakelin R, Chang SS, Baresi L, Chamberlain JS. An intracellular delivery vehicle for protein transduction of micro-dystrophin. Journal Of Drug Targeting 2005, 13: 81-87. PMID: 15823959, DOI: 10.1080/10611860400029002.Peer-Reviewed Original Research
2004
Antibody-mediated transduction of p53 selectively kills cancer cells.
Weisbart RH, Hansen JE, Chan G, Wakelin R, Chang SS, Heinze E, Miller CW, Koeffler PH, Yang F, Cole GM, Min YS, Nishimura RN. Antibody-mediated transduction of p53 selectively kills cancer cells. International Journal Of Oncology 2004, 25: 1867-73. PMID: 15547728, DOI: 10.3892/ijo.25.6.1867.Peer-Reviewed Original ResearchConceptsCancer cellsWild-type p53Expression of MDM2Cancer cell linesTransduction of p53Potential efficacyCertain cancersNon-specific toxicityFunctional defectsHuman cancersP53Cell linesCancerResult of mutationsGene therapyPrimary cellsViral vectorsCellsVivoNuclear exclusionTherapyFusion proteinFv fragmentProtein transductionAntibodies
2003
Vascular Endothelial Growth Factor Expression, β-Catenin Tyrosine Phosphorylation, and Endothelial Proliferative Behavior: A Pathway for Transformation?
Ilan N, Tucker A, Madri JA. Vascular Endothelial Growth Factor Expression, β-Catenin Tyrosine Phosphorylation, and Endothelial Proliferative Behavior: A Pathway for Transformation? Laboratory Investigation 2003, 83: 1105-1115. PMID: 12920240, DOI: 10.1097/01.lab.0000083531.84403.8b.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, BlockingAntigens, CD1beta CateninCell DivisionCell Transformation, NeoplasticCytoskeletal ProteinsEndothelial Growth FactorsEndothelium, VascularExtracellular Matrix ProteinsHemangioendotheliomaHumansIntercellular Signaling Peptides and ProteinsLymphokinesPhosphorylationTrans-ActivatorsTumor Cells, CulturedTyrosineUmbilical VeinsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth FactorsConceptsVascular endothelial growth factorEOMA cellsCD1 levelsFlk-1Vascular endothelial growth factor (VEGF) expressionExogenous vascular endothelial growth factorEndogenous vascular endothelial growth factorEndothelial cell tumorsGrowth factor expressionEndothelial growth factorTyrosine phosphorylationNuclear beta-catenin localizationNuclear localizationProliferative behaviorΒ-catenin tyrosine phosphorylationHuman endothelial cellsComponent expression levelsCD1 expressionCell tumorsCommon tumorsImmune complex kinase assayEndothelial cell transformationMitogen-activated protein kinase activationPrimary human endothelial cellsAutocrine loopPulmonary Expression of Leukemia Inhibitory Factor Induces B Cell Hyperplasia and Confers Protection in Hyperoxia*
Wang J, Chen Q, Corne J, Zhu Z, Lee CG, Bhandari V, Homer RJ, Elias JA. Pulmonary Expression of Leukemia Inhibitory Factor Induces B Cell Hyperplasia and Confers Protection in Hyperoxia*. Journal Of Biological Chemistry 2003, 278: 31226-31232. PMID: 12782633, DOI: 10.1074/jbc.m301820200.Peer-Reviewed Original ResearchConceptsLeukemia inhibitory factorB-cell hyperplasiaCell hyperplasiaIL-6Protective effectTransgenic miceAlveolar-capillary protein leakB cell-mediated responsesInhibitory factorAdult respiratory distress syndromeHyperoxic acute lung injuryAcute lung injuryRespiratory distress syndromeCell-mediated responsesInduction of interleukinBronchoalveolar lavage cellularityHuman leukemia inhibitory factorLung injuryDistress syndromeLavage cellularityPulmonary expressionProtein leakRespiratory effectsOxidant injuryB lymphocytesIn Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor
Yano S, Herbst RS, Sone S. In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor. Methods In Molecular Medicine 2003, 74: 391-398. PMID: 12415710, DOI: 10.1385/1-59259-323-2:391.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCapillary PermeabilityCell DivisionCells, CulturedEndothelial Growth FactorsEndothelium, VascularHumansImmunoglobulin GIn Vitro TechniquesIntercellular Signaling Peptides and ProteinsLymphokinesMaleMiceMice, Inbred C57BLMice, NudeReceptors, Vascular Endothelial Growth FactorRecombinant ProteinsTetrazolium SaltsThiazolesThymidineVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsNon-small cell lung cancerVascular endothelial growth factorLung cancerEarly-stage non-small cell lung cancerCell lung cancerNormal bronchial epitheliumEndothelial growth factorNew blood vesselsBronchial dysplasiaPoor prognosisPrimary tumorLung carcinogenesisMicrovascular densityBronchial epitheliumSolid tumorsBlood vesselsGrowth factorTumorsMetabolic demandsVivo assaysCancerEarly stagesCarcinomaPrognosisHyperplasia
2002
Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis.
Kisley L, Barrett B, Bauer A, Dwyer-Nield L, Barthel B, Meyer A, Thompson D, Malkinson A. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Research 2002, 62: 6850-6. PMID: 12460898.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsButylated HydroxytolueneCarcinogensEndothelial Growth FactorsImmunohistochemistryIntercellular Signaling Peptides and ProteinsLungLung NeoplasmsLymphokinesMacrophages, AlveolarMaleMiceMice, KnockoutNitric OxideNitric Oxide SynthaseNitric Oxide Synthase Type IIUrethaneVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsLung tumor multiplicityLung tumorigenesisLung tumorsMouse lung tumorigenesisINOS deficiencyINOS (-/-) miceNitric oxideLung inflammationTumor multiplicityLung cancer chemopreventive agentNitric oxide synthase contentInducible nitric oxide synthaseInducible nitric oxide synthase (iNOS) contentMurine lung tumorigenesisVascular endothelial growth factor (VEGF) expressionChronic lung inflammationRole of iNOSLung cancer patientsWhole lung extractsCOX-2 contentAlveolar macrophage infiltrationNitric oxide synthaseWild-type miceBronchiolar Clara cellsMouse lung tumorsDisrupted synaptic development in the hypoxic newborn brain
Curristin SM, Cao A, Stewart WB, Zhang H, Madri JA, Morrow JS, Ment LR. Disrupted synaptic development in the hypoxic newborn brain. Proceedings Of The National Academy Of Sciences Of The United States Of America 2002, 99: 15729-15734. PMID: 12438650, PMCID: PMC137784, DOI: 10.1073/pnas.232568799.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnimals, NewbornApoptosisAtmosphere Exposure ChambersBrain Damage, ChronicCell DifferentiationCytoskeletonDisease Models, AnimalDNA, ComplementaryEndothelial Growth FactorsGene Expression ProfilingHypoxiaHypoxia-Inducible Factor 1, alpha SubunitHypoxia, BrainIntercellular Signaling Peptides and ProteinsLymphokinesMembrane ProteinsMiceMice, Inbred C57BLMicrotubulesNerve Tissue ProteinsOligodendrogliaOligonucleotide Array Sequence AnalysisStress, PhysiologicalSynapsesSynaptic TransmissionTranscription FactorsTranscription, GeneticVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsPostnatal hypoxiaCerebral maturationGlial maturationNewborn brainSynaptic maturationPresynaptic functionPostsynaptic functionSublethal hypoxiaSynaptic developmentHealth crisisHypoxiaCognitive disabilitiesBrainMaturation programMaturationDysynchronyNeuropathologyInfantsNeurotransmissionCohortProtein assaysMiceHypoxicPhase I study of recombinant human endostatin in patients with advanced solid tumors.
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O’Reilly M, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. Journal Of Clinical Oncology 2002, 20: 3792-803. PMID: 12228199, DOI: 10.1200/jco.2002.11.061.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAngiogenesis InhibitorsCollagenCollagen Type XVIIIE-SelectinEndostatinsEndothelial Growth FactorsFemaleFibroblast Growth Factor 2Hematologic DiseasesHumansImmunoglobulinsInfusions, IntravenousLymphokinesMagnetic Resonance ImagingMaleMaximum Tolerated DoseMiddle AgedNeoplasmsPeptide FragmentsRecombinant ProteinsTime FactorsTissue DistributionVascular Cell Adhesion Molecule-1Vascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsRh-EndoConcentration-time curveRecombinant human endostatinSerum markersPreclinical modelsSolid tumorsHuman endostatinDose-limiting toxic effectAntitumor activityTwo-compartmental open modelAdvanced solid tumorsPhase I trialCentral line accessDose-finding trialMinor antitumor activityI trialIntravenous bolusSerum biomarkersSerum antibodiesPharmacokinetic dispositionAllergic reactionsPatientsPharmacokinetic profileDose levelsPhase ITargeted therapy in non-small-cell lung cancer.
Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology 2002, 16: 19-24. PMID: 12375797.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungClinical Trials as TopicEndothelial Growth FactorsErbB ReceptorsHumansIntercellular Signaling Peptides and ProteinsLung NeoplasmsLymphokinesProtein Kinase CVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsCell lung cancerLung cancerSuch new agentsNew agentsVascular endothelial growth factor inhibitorsPlatinum-based combination therapyEGFR tyrosine kinase inhibitorsGrowth factor receptor inhibitorsNew biologic therapiesGrowth factor inhibitorsEpithelial growth factor receptor inhibitorTyrosine kinase inhibitorsSpecific biologic pathwaysDevelopment of agentsSignal transduction inhibitorsMaintenance therapyBiologic therapyCytotoxic chemotherapyStages of treatmentFactor inhibitorsCombination therapyTargeted therapyReceptor inhibitorsRadiation therapyClinical investigationDephosphorylation of Endothelial Nitric-oxide Synthase by Vascular Endothelial Growth Factor IMPLICATIONS FOR THE VASCULAR RESPONSES TO CYCLOSPORIN A*
Kou R, Greif D, Michel T. Dephosphorylation of Endothelial Nitric-oxide Synthase by Vascular Endothelial Growth Factor IMPLICATIONS FOR THE VASCULAR RESPONSES TO CYCLOSPORIN A*. Journal Of Biological Chemistry 2002, 277: 29669-29673. PMID: 12050171, DOI: 10.1074/jbc.m204519200.Peer-Reviewed Original ResearchConceptsENOS dephosphorylationSerine 116MAP kinase pathway inhibitor U0126Protein phosphatase pathwaysPhosphorylation-deficient mutantDependent protein phosphatasePhosphorylation state-specific antibodiesWild-type enzymeVascular endothelial growth factorProtein kinase C inhibitor calphostinPathway inhibitor U0126Activation of calcineurinProtein phosphataseInhibitor of calcineurinPhosphatase pathwaysENOS agonistsProtein kinaseEndothelial cellsAlanine residuesDephosphorylationDependent enzymesInhibitor U0126Dephosphorylation of eNOSCultured endothelial cellsEnzyme activityCorticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization
Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL, Vale WW, Lee KF. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proceedings Of The National Academy Of Sciences Of The United States Of America 2002, 99: 7734-7739. PMID: 12032352, PMCID: PMC124337, DOI: 10.1073/pnas.102187099.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsCapillariesCell DivisionCells, CulturedEndothelial Growth FactorsEndothelium, VascularGene Expression RegulationLymphokinesMiceMice, KnockoutMuscle, Smooth, VascularNeovascularization, PhysiologicReceptors, Corticotropin-Releasing HormoneVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsCorticotropin-releasing factor receptor 2Smooth muscle cellsCapillary tube formationTube formationCell cycle progressionVascular endothelial growth factorFactor receptor 2Protein phosphorylationRetinoblastoma proteinCycle progressionLigand activationReceptor 2Adult neovascularizationCRFR2-deficient miceCell proliferationIschemic cardiovascular diseasePotential targetAdult vesselsQuiescent stateMuscle cellsEndothelial growth factorGrowth factorSMC proliferationWestern blotCollagen gelsAssessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin
Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, Roach JS, Kalimi SK, Ozaki K, Fogler WE, Bryant JL, Herbst R, Abbruzzes J, Kim EE, Podoloff DA. Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin. Cancer Biotherapy & Radiopharmaceuticals 2002, 17: 233-246. PMID: 12030117, DOI: 10.1089/108497802753773856.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCollagenCysteineEndostatinsEndothelial Growth FactorsFemaleFibroblast Growth Factor 2In Situ Nick-End LabelingIntercellular Signaling Peptides and ProteinsInterleukin-8LymphokinesMammary Neoplasms, ExperimentalNeovascularization, PathologicPaclitaxelPeptide FragmentsRadionuclide ImagingRatsRats, Inbred F344TechnetiumTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsTumor-bearing ratsAnti-angiogenesis therapyTreatment responseTumor uptakeTUNEL assayAnti-angiogenic treatment responseTumor vascular densityIL-8 expressionTumor-bearing animal modelsCount density ratiosCell viabilityPrognostic indicatorMicrovessel densityVascular densityAnimal modelsEndostatin therapyAntiangiogenic effectsMetastatic potentialTherapyUptake doseCellular uptake assaysEndostatinTissue distributionRatsEthylenedicysteine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply